# 410 Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/410-medical

- Industry: Medical Devices & Equipment
- Headquarters: Durham, US
- Website: www.410medical.com
- Total disclosed funding: $35M
- Latest round: Series B (Mar 17, 2025)
- Investors on record: 11

## About

410 Medical, Inc. is a U.S.-based company specializing in innovative medical devices that enhance fluid delivery for critically ill patients, improving emergency care outcomes. Founded in 2013 and based in Durham, US, 410 Medical, Inc. focuses on developing solutions for rapid blood and fluid delivery. The company is currently led by CEO Kyle Chenet. 410 Medical, Inc. offers LifeFlow, a system designed for rapid blood and fluid delivery, crucial for patients experiencing severe gastrointestinal bleeding and other emergencies. Its key product, the LifeFlow Fluid Infuser, significantly accelerates fluid administration in life-threatening situations. The recent addition, LifeFlow PLUS, is a portable, hand-operated device aimed at patients in hemorrhagic shock, catering to healthcare providers in hospitals, emergency medical services, military units, and pediatric care facilities, mainly in North America and Europe. 410 Medical, Inc. generates revenue through direct B2B sales of its LifeFlow medical devices to healthcare institutions. Hospitals purchase the LifeFlow Fluid Infuser and LifeFlow PLUS, with pricing reflecting the advanced technology and effectiveness of the products in critical care settings. The company focuses on nurturing long-term client relationships while providing training and resources for optimal product usage. In July 2026, 410 Medical, Inc. raised USD 12 million in venture funding led by Orlando Health Ventures, with participation from Hatteras Venture Partners, Ballad Ventures, OSF Ventures, Rex Health Ventures, CU Healthcare Innovation Fund, Sarnova, Inc., Catalyst by Wellstar and TGH Ventures. The company will use the funding to scale its commercial operations and support the launch of LifeFlow's next-generation infuser.

## Funding rounds

- Series B, Mar 17, 2025, $14M — Hatteras Venture Partners, Sarnova, Inc., OSF Ventures, WakeMed Health & Hospitals, Rex Health Ventures, Orlando Health Ventures, CU Healthcare Innovation Fund, Ballad Ventures
- Series B, Oct 26, 2022, $10M — Hatteras Venture Partners, OSF Ventures, WakeMed Health & Hospitals, Orlando Health Ventures, Ballad Ventures, Catalyst by Wellstar
- Series A, Oct 21, 2019, $7.6M — Hatteras Venture Partners, Sovereign's Capital, OSF Ventures
- Series A, Mar 23, 2017, $3.3M — Bios Partners, Sovereign's Capital

## Investors

- Bios Partners (https://capitalatlas.ai/funds/bios-partners) — Series A
- Sovereign's Capital (https://capitalatlas.ai/funds/sovereign-s-capital) — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A, Series B
- OSF Ventures (https://capitalatlas.ai/funds/osf-ventures) — Series A, Series B
- WakeMed Health & Hospitals — Series B
- Orlando Health Ventures — Series B
- Ballad Ventures (https://capitalatlas.ai/funds/ballad-ventures) — Series B
- Catalyst by Wellstar (https://capitalatlas.ai/funds/catalyst-by-wellstar) — Series B
- Sarnova, Inc. — Series B
- Rex Health Ventures (https://capitalatlas.ai/funds/rex-health-ventures) — Series B
- CU Healthcare Innovation Fund (https://capitalatlas.ai/funds/cu-healthcare-innovation-fund) — Series B